These aren't the glory days for med-tech giant Medtronic (NYSE:MDT), as fiscal 2014 will be a pretty weak year from a growth perspective ahead of some significant new product launches in 2015. Even with a high-quality name like Medtronic, that lack of growth can lead to shares languishing as investors are attracted to (or distracted by) more impressive-looking stories in the short term. Although I'm not a passionate bull on Medtronic shares by any stretch, the stock is pretty much what passes for a bargain these days in the larger segment of this industry and I think it's a respectable core holding.
 
Quarterly Results Pretty “Meh” For Medtronic
There wasn't a lot to complain about in Medtronic's fiscal first quarter, but then neither was there much to celebrate. Like many others in this sector, it was a workmanlike quarter for a market still weighed down by adverse pricing, reimbursement, and utilization trends.

SEE: A Checklist For Successful Medical Technology Investment
 
Revenue rose 2% as reported, or about 3% on an organic basis – very slightly below the average of sell-side estimates. Margins were likewise okay-ish. Gross margin was down about 70bp from last year and either 10bp or 50bp below the average (I've seen two different “consensus” figures). Likewise, operating income rose 3% and operating margin expanded slightly (40bp), but that was either just barely above expectation, or a bit below where sell-side numbers were. 
 
If there was one bright spot to the quarter, it was in the international business. Medtronic's international sales rose 15% on a constant currency basis this quarter.
 
Segment Results Mixed As Well
Not unlike the overall results, Medtronic's line-item results were mixed this quarter.
 
Overall cardiac rhythm management (CRM) sales were up about 2%, or just slightly below expectations. While pacemaker sales were stronger than expected (up 6%), analysts stubbornly refuse to accept that St. Jude (NYSE:STJ) and Boston Scientific (NYSE:BSX) are doing alright in ICDs and I think the company's “weak” performance (down 2%, but 3% below expectations) has less to do with the business than those expectations. On a brighter note, atrial fibrilation-related sales were up 22%.
 
Spine was weaker than expected (down 1%), as the company continues to suffer from its problems with the orthobiologic Infuse. Excluding Infuse, Medtronic isn't doing terribly relative to Johnson & Johnson (NYSE:JNJ) or Stryker (NYSE:SYK), but given that biologics are a large part of most spine care businesses, I wouldn't agree that you should exclude it.
 
Cardio was solid, up 6% and 5% ahead of expectations, as CoreValve continues to do well and the stent business is alright. Neuro and diabetes were more mixed – not bad relative to expectations, but not great in absolute terms (up 3% and 1%, respectively), as the new Boston Scientific Precision Spectra gained some traction and the diabetes business suffered from deferrals ahead of the new 530G pump.
 
One bright spot was the Surgical Tech business – up 13% and well ahead (more than 10%) of expectations. With the sluggishness in diabetes, Surg Tech could move Diabetes down to the smallest reported segment momentarily (though I expect the 530G pump to ultimately revive sales).
 
Holding Its Own For Now
All things considered, this is a good enough result for Medtronic. The company is certainly suffering from the launch of new products from rivals and the erosion of the Infuse business, but none of those were (or should have been) unexpected developments. Moreover, I do believe that the company can gain strong initial share with its Simplicity renal denervation product in 2015, as well as the Admiral drug-eluting balloon. I'm a little less certain about the CoreValve launch in the U.S., given Edwards' (NYSE:EW) disappointing U.S. sales, but I still believe it will be a significant product that moves the needle on revenue growth.

SEE: Compound Annual Growth Rate: What You Should Know
 
The Bottom Line
Medtronic has a trailing free cash flow CAGR of 7%, but I'm forecasting less than half that growth rate for the next decade, as the company faces more challenging headwinds from reimbursement, competition, and its own size. Even so, a 3% free cash flow growth rate supports a fair value in range of the high $50s to low $60s, and that appreciation potential isn't too bad for the sector these days. Factor in the company's commitment to establishing itself as a player in emerging markets, and I think you can make a decent enough case for buying Medtronic shares today.
 
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.
 
 

Related Articles
  1. Insurance

    A Checklist For Successful Medical Technology Investment

    Find an investment that will give your portfolio a shot in the arm.
  2. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  3. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  4. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  5. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  6. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  7. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  8. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  9. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  10. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center